Asset Management Ventures

Asset Management Ventures is a venture capital investment firm founded in 1965 by Franklin "Pitch" Johnson, with its headquarters in Menlo Park, California. The firm specializes in providing early-stage financing to innovative companies primarily in the digital health, information technology, and life sciences sectors. Over the years, Asset Management Ventures has supported the growth of several groundbreaking companies, highlighting its commitment to fostering advancements in these fields. As a Registered Investment Adviser, the firm is dedicated to identifying and nurturing promising startups that have the potential to make significant impacts in their respective industries.

Chen, Jialu

Principal

Skip Fleshman

Partner

Richard Simoni Ph.D

Partner

143 past transactions

Autonomize

Venture Round in 2023
Autonomize AI, a pioneering force in the AI-driven healthcare sector, is revolutionizing the industry by developing advanced AI copilots. These AI copilots meticulously organize, contextualize, and summarize unstructured data, significantly reducing the administrative burden on healthcare knowledge workers. This enables them to make data-driven decisions swiftly, ultimately enhancing patient outcomes. As a founding member of CancerX, the US President Biden’s Cancer Moonshot initiative, Autonomize AI is at the forefront of innovation in the fight against cancer. Our esteemed clientele includes Top 20 pharmaceutical companies, Fortune 100 Payors, and leading life sciences firms. By leveraging cutting-edge technologies such as natural language processing (NLP), machine learning (ML), and advanced data analytics, we are transforming the healthcare landscape and setting new standards for precision and efficiency.

Array Insights

Venture Round in 2022
Secure AI Labs helps businesses access proprietary data by protecting it during analysis. It protects data by digitally enforcing data-use policies and enable data owners control who, how, and where the data is used, even after sharing. The company's encrypted analytics platform keeps data and algorithms secure at every step. It provides bioinformatics and machine learning to develop AI models which users can access from a diverse library. Businesses can access data easily without the liability of working with personal or proprietary information. Secure AI Labs was founded on 2017 and is based in Cambridge, Massachusetts.

LegalMate

Seed Round in 2022
We believe that every person has the right to access legal help, regardless of their financial background. In the United States, the Legal Services Corporation states that 86% of civil legal problems reported by low-income Americans received inadequate or no legal help.¹ While legal aid and pro bono services are helping, there are still many people left to manage their legal issues with no access to professional representation or guidance. Many law firms report high demand to offer payment plans, which can be a challenge for firms to manage and can result in limited options for their clients. Our solution is to provide financing at a low cost. The LegalMate model ensures law firms receive their fees upfront whilst abiding by IOLTA and ABA guidelines and empowers more clients to access the legal help they need on their own terms.

Pluto Health

Seed Round in 2022
Pluto Health develops consumer health technology applications designed to aggregate electronic health record data. The company's application finds, integrates, and automates insights from their medical records and data across different health systems, pharmacies, and labs and also reminds users about tasks such as paying healthcare bills, tracking medications, and sharing health data with providers, empowering patients with tools for better care.

Outcomes4Me

Series A in 2021
Outcomes4Me is an AI-driven patient empowerment platform that helps cancer patients take a proactive approach to their care, gaining access to personalized, evidence-based treatment options and information. The company is on a mission to democratize healthcare by providing real-time, evidence-based clinical information to cancer patients, ensuring they can effectively navigate through their disease and improve their outcomes. In doing so, Outcomes4Me is working to promote health equity by generating deeper insights that improve care, and accelerating research and access to innovation. Based in Boston, Massachusetts, Outcomes4Me is a woman-led company of seasoned healthcare, oncology, pharmaceutical, consumer, and technology veterans. For more information, visit www.outcomes4me.com

Carta Healthcare

Series A in 2021
Carta Healthcare empowers hospitals to personalize the delivery of care to the individual needs of each patient. The approach Carta Healthcare is advocating and enabling to find past patients similar to the current one being treated, quantify what exactly happened to them during their journey through the hospital (this is where our model comes in), and use machine learning to project what the particular patient in question will need, and what the patient can expect their experience to be in the hospital.

Array Insights

Seed Round in 2020
Secure AI Labs helps businesses access proprietary data by protecting it during analysis. It protects data by digitally enforcing data-use policies and enable data owners control who, how, and where the data is used, even after sharing. The company's encrypted analytics platform keeps data and algorithms secure at every step. It provides bioinformatics and machine learning to develop AI models which users can access from a diverse library. Businesses can access data easily without the liability of working with personal or proprietary information. Secure AI Labs was founded on 2017 and is based in Cambridge, Massachusetts.

Outcomes4Me

Seed Round in 2020
Outcomes4Me is an AI-driven patient empowerment platform that helps cancer patients take a proactive approach to their care, gaining access to personalized, evidence-based treatment options and information. The company is on a mission to democratize healthcare by providing real-time, evidence-based clinical information to cancer patients, ensuring they can effectively navigate through their disease and improve their outcomes. In doing so, Outcomes4Me is working to promote health equity by generating deeper insights that improve care, and accelerating research and access to innovation. Based in Boston, Massachusetts, Outcomes4Me is a woman-led company of seasoned healthcare, oncology, pharmaceutical, consumer, and technology veterans. For more information, visit www.outcomes4me.com

Lark

Series C in 2020
Lark is a developer of chronic disease prevention and management platform used to prevent chronic conditions. The company uses cutting-edge AI combined with human coaches and connected devices to provide real-time, personalized, 24/7 support, and counseling to help users make healthier choices and manage their conditions. Its CDC-recognized Diabetes Prevention Program, Wellness Program, Diabetes Care Program, and Hypertension Program have 1.5 million users and have demonstrated clinically validated improved health outcomes published in 11 peer-reviewed journals and analyst reports. Lark was founded by Julia Hu and Jeff Zira in 2011 and is headquartered in Mountain View, California.

Reify Health

Series B in 2020
Reify Health provides cloud-based software that helps accelerate the development of new, life-saving therapies. The company's system accelerates enrollment timelines and the overall pace of research, enabling research sponsors and coordinators to focus on the actions that impact clinical research success. Reify Health product StudyTeam is a cloud-based software that helps clinical trial teams achieve faster, more predictable enrollment while eliminating the tedious work that saps productivity and study budget. It gives sponsors, CROs, and clinical research sites earlier visibility into the full enrollment picture, and the insight they need to focus on people and capital on work that yields the greatest return.

Unnatural Products

Seed Round in 2019
Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets. Unnatural Products was founded in 2017 and is headquartered in Santa Cruz, California.

Aegis Surgical

Convertible Note in 2019
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis.

Arterys

Convertible Note in 2019
Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions.

UniKey Technologies

Convertible Note in 2019
UniKey Technologies offers a mobile platform to replace keys, codes, and passwords by turning a smartphone into a universal electronic key. It develops and offers a “touch-to-open” technology, through which a smartphone can stay in a pocket or purse to keep hands free; delivers patent-pending intelligence that detects whether an authorized user is inside or outside of the home or building before granting access to help prevent unauthorized entry; and provides multiple levels of security. The company partners with lock manufactures, including Kwikset and Weiser to create smart locks such as Kevo. Its cloud-based lock management solution enables multifamily properties to manage multiple locks for each unit. It brings leading smart lock and access control technology to address the needs of small and large commercial businesses. UniKey’s eKey systems, paired with its partners’ locks for hospitality, enable complete key management. UniKey Technologies was founded in 2010 by Phil Dumas and is based in Florida, United States.

Welkin Health

Series B in 2019
Welkin is patient management software that guides teams through their care, keeping them on track. It tells health workers when to do what, focusing attention on the people who need it, when they need it. Their software makes care delivery seamless and patient-centered, empowering health care teams to build meaningful relationships with their patients.

Mightier

Series A in 2019
Mightier is a gaming platform and family program scientifically-proven to help kids regulate their emotions. It is a bioresponsive program that harnesses the mind-body connection to build emotional regulation in its players. Its program of bioresponsive video games, developed at Boston Children's Hospital and Harvard Medical School, aims to help children with behavioral and emotional challenges learn how to harness emotions in daily life. Mightier was founded in 2016 and is headquartered in Boston, Massachusetts.

Signal Vine

Convertible Note in 2019
Signal Vine is a text messaging platform that uses Blended Messaging to reach students where they operate most while incorporating the benefits of AI to save staff time. The company's s platform empowers customers to combine text messaging with student data to deliver personalized information, prompt timely action, and ultimately improve outcomes for higher education organizations, nonprofits, and government programs. By nudging students, alumni, and staff with personal messages on key deadlines, appointments, and offers of support, administrators can improve engagement and in turn enrollment and persistence. It was founded in 2013 and is headquartered in Alexandria, Virginia, United States.

Carta Healthcare

Convertible Note in 2019
Carta Healthcare empowers hospitals to personalize the delivery of care to the individual needs of each patient. The approach Carta Healthcare is advocating and enabling to find past patients similar to the current one being treated, quantify what exactly happened to them during their journey through the hospital (this is where our model comes in), and use machine learning to project what the particular patient in question will need, and what the patient can expect their experience to be in the hospital.

InCarda Therapeutics

Series B in 2018
InCarda Therapeutics is a clinical-stage drug delivery company pioneering a novel approach of treating acute cardiovascular diseases/conditions by the inhalation route. Lead product is InRhythm, an inhaled formulation of an antiarrhythmic drug to treat acute paroxysmal atrial fibrillation events within minutes at home, at work, or anywhere. Completed Phase 1 and currently advancing lead product through Phase 2. InCarda Therapeutics was founded in Newark, California.

Properly

Series A in 2018
Properly is a visual checklist tool that lets property owners share turnover instructions with cleaning pros effortlessly. Properly's mission is to have hosts and property managers get the same streamlined results during every guest turnover cleaning, and for professional cleaners to understand their clients' expectations and get recognized for stellar work.

Aegis Surgical

Convertible Note in 2017
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis.

3T Biosciences

Seed Round in 2017
Founded in 2017, 3T Biosciences is an immunotherapy company headquartered in Menlo Park, California.

Huiseoul

Seed Round in 2017
Huiseoul (Trillionaire) is an e-commerce that provides personalized skincare counselling and skincare products. It focuses on providing Korean beauty products exclusively to China. It also develops front-end, back-end, API and chat server, and mobile application for a conversational e-commerce service.

Freenome

Series A in 2017
Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention.

Signal Vine

Series A in 2017
Signal Vine is a text messaging platform that uses Blended Messaging to reach students where they operate most while incorporating the benefits of AI to save staff time. The company's s platform empowers customers to combine text messaging with student data to deliver personalized information, prompt timely action, and ultimately improve outcomes for higher education organizations, nonprofits, and government programs. By nudging students, alumni, and staff with personal messages on key deadlines, appointments, and offers of support, administrators can improve engagement and in turn enrollment and persistence. It was founded in 2013 and is headquartered in Alexandria, Virginia, United States.

Indi Molecular

Series A in 2017
Indi Molecular is an emerging life sciences company that is developing a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. PCCs were created in collaboration with the California Institute of Technology using “click chemistry,” a synthetic process that allows scientists to permanently join (“click”) together molecular components with remarkable precision and stability. PCCs offer the promise of improved selectivity, superior binding affinity, fully synthetic composition and a vastly low molecular weight compared to monoclonal antibodies, the current standard for identifying biomarkers in most diagnostics platforms – and in many therapeutic uses. The company launched as a spinout from its parent company Integrated Diagnostics (Indi) in 2013 with a $1.5 million seed round led by InterWest Partners together with several angel investors.

UniKey Technologies

Convertible Note in 2017
UniKey Technologies offers a mobile platform to replace keys, codes, and passwords by turning a smartphone into a universal electronic key. It develops and offers a “touch-to-open” technology, through which a smartphone can stay in a pocket or purse to keep hands free; delivers patent-pending intelligence that detects whether an authorized user is inside or outside of the home or building before granting access to help prevent unauthorized entry; and provides multiple levels of security. The company partners with lock manufactures, including Kwikset and Weiser to create smart locks such as Kevo. Its cloud-based lock management solution enables multifamily properties to manage multiple locks for each unit. It brings leading smart lock and access control technology to address the needs of small and large commercial businesses. UniKey’s eKey systems, paired with its partners’ locks for hospitality, enable complete key management. UniKey Technologies was founded in 2010 by Phil Dumas and is based in Florida, United States.

Amygdala Neuroscience

Seed Round in 2017
Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse. In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies. Their initial development focus is for smoking cessation with parallel development efforts for cocaine, opioid and alcohol use disorders.

Thunder

Series B in 2017
Thunder Creative Management Platform removes creative friction to allow advertisers to build more ads, faster. By doing so, Thunder scales ad creatives across devices, formats, and volume. Thunder's ad platform powers display, social, and mobile advertising for over 100 brands, media companies, and agencies. Notable customers include InterContinental Hotels Group, Time Warner Cable, Charter Communications, and Hearst.

Twist Bioscience

Venture Round in 2017
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development. At Twist Bioscience Corporation, they work in the service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. They believe that the faster their customers succeed, the better for all of them, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to their customers. their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. Twist Bioscience was founded in 2013 and is headquartered in San Francisco, California.

Freenome

Series A in 2017
Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention.

Welkin Health

Series A in 2017
Welkin is patient management software that guides teams through their care, keeping them on track. It tells health workers when to do what, focusing attention on the people who need it, when they need it. Their software makes care delivery seamless and patient-centered, empowering health care teams to build meaningful relationships with their patients.

3T Biosciences

Convertible Note in 2017
Founded in 2017, 3T Biosciences is an immunotherapy company headquartered in Menlo Park, California.

Womply

Series B in 2016
Our mission is to help local businesses thrive in a digital world. Founded in 2011, Womply is a local commerce platform that provides apps, APIs, marketing, and financial tools to make local commerce happen for over 500,000 American businesses and their customers. All of Womply’s products and services are powered by the Womply Commerce Graph, a proprietary data asset that offers the most complete view of local commerce.

Mozio

Non Equity Assistance in 2016
Mozio is an airport ground transportation search engine. We help you travel that final mile from the airport to your final destination. Mozio originated out of founder David Litwak's travels, where he was constantly frustrated by flying into new destinations and realizing he had no clue how to actually get into the city. Mozio aggregates all the local taxis, limos, public transit, shared-ride shuttles, airporters, rideshare etc. to help you navigate all the local options and make sure you get the best deal. We have raised a small seed round from Amidzad Partners, and a few angels, one of whom is the Chairman of the Board @ Orbitz. We are super excited to make this dream a reality!

InCarda Therapeutics

Venture Round in 2016
InCarda Therapeutics is a clinical-stage drug delivery company pioneering a novel approach of treating acute cardiovascular diseases/conditions by the inhalation route. Lead product is InRhythm, an inhaled formulation of an antiarrhythmic drug to treat acute paroxysmal atrial fibrillation events within minutes at home, at work, or anywhere. Completed Phase 1 and currently advancing lead product through Phase 2. InCarda Therapeutics was founded in Newark, California.

Evidation Health

Series B in 2016
Evidation measures health in everyday life and enables anyone to participate in groundbreaking research and health programs. Built upon a foundation of user privacy and control over permissioned health data, Evidation's Achievement platform is trusted by millions of individuals—generating data with unprecedented speed, scale, and rigor. We partner with leading healthcare companies to understand health and disease outside the clinic walls. Guided by our mission to enable and empower everyone to participate in better health outcomes, Evidation is working to bring people individualized, proactive, and accessible healthcare—faster. Founded in 2012, Evidation Heath is headquartered in California. We collaborate as a distributed team with additional offices around the globe. To learn more, visit evidation.com, or follow us on Twitter @evidation

ViewPoint Therapeutics

Series A in 2016
ViewPoint Therapeutics is a biotechnology company dedicated to the development of treatments for diseases of protein misfolding, including cataracts. The company's crystallin stabilizers include a small molecule that is active in preclinical models of age-related cataracts via a target-based screening and optimization effort, providing physicians with drugs to prevent or reverse protein misfolding, which is implicated in numerous common disorders of aging including cataracts, presbyopia, and neurodegenerative diseases.

Arterys

Series A in 2016
Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions.

SensOmics

Seed Round in 2016
SensOmics invents cutting-edge technologies to detect paediatric diseases early. They integrate genomics with clinical informatics, electrical engineering, and artificial intelligence.

Aegis Surgical

Series B in 2016
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis.

RallyPoint

Series B in 2015
RallyPoint is an online military network with 2 million service members, veterans, and their civilian supporters (family, recruiters, etc.). RallyPoint's mission is to help all members of the military community lead more successful and fulfilling lives. Members can build their professional network, connect with other members in a safe environment, and explore career opportunities both within the military and in the private sector. Bob McDonald, the retired P&G CEO and the 8th Secretary of Veterans Affairs is the chairman of RallyPoint's board. RallyPoint provides employers highly targeted tools for hiring from and advertising into the military community.

Welldoc

Series B in 2015
Welldoc develops technology solutions to support chronic disease management. They work with leaders across the healthcare, life science, and medical device industries to ensure the solutions they develop scale and integrate into their existing workflows and systems. The Welldoc platform offers support for multiple chronic conditions, ecosystem solutions, and artificial intelligence.

Profusa

Series B in 2015
Profusa, Inc. operates in the health care sector. It is dedicated to the development of a new generation of biointegrated sensors that empowers the individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. The company was incorporated in 2009 and is based in Cupertino, California.

Arterys

Series A in 2015
Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions.

Thunder

Series B in 2015
Thunder Creative Management Platform removes creative friction to allow advertisers to build more ads, faster. By doing so, Thunder scales ad creatives across devices, formats, and volume. Thunder's ad platform powers display, social, and mobile advertising for over 100 brands, media companies, and agencies. Notable customers include InterContinental Hotels Group, Time Warner Cable, Charter Communications, and Hearst.

Welkin Health

Seed Round in 2015
Welkin is patient management software that guides teams through their care, keeping them on track. It tells health workers when to do what, focusing attention on the people who need it, when they need it. Their software makes care delivery seamless and patient-centered, empowering health care teams to build meaningful relationships with their patients.

Twist Bioscience

Series C in 2015
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development. At Twist Bioscience Corporation, they work in the service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. They believe that the faster their customers succeed, the better for all of them, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to their customers. their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. Twist Bioscience was founded in 2013 and is headquartered in San Francisco, California.

Thunder

Venture Round in 2015
Thunder Creative Management Platform removes creative friction to allow advertisers to build more ads, faster. By doing so, Thunder scales ad creatives across devices, formats, and volume. Thunder's ad platform powers display, social, and mobile advertising for over 100 brands, media companies, and agencies. Notable customers include InterContinental Hotels Group, Time Warner Cable, Charter Communications, and Hearst.

Aegis Surgical

Convertible Note in 2015
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis.

Amygdala Neuroscience

Venture Round in 2015
Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse. In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies. Their initial development focus is for smoking cessation with parallel development efforts for cocaine, opioid and alcohol use disorders.

Evidation Health

Series A in 2014
Evidation measures health in everyday life and enables anyone to participate in groundbreaking research and health programs. Built upon a foundation of user privacy and control over permissioned health data, Evidation's Achievement platform is trusted by millions of individuals—generating data with unprecedented speed, scale, and rigor. We partner with leading healthcare companies to understand health and disease outside the clinic walls. Guided by our mission to enable and empower everyone to participate in better health outcomes, Evidation is working to bring people individualized, proactive, and accessible healthcare—faster. Founded in 2012, Evidation Heath is headquartered in California. We collaborate as a distributed team with additional offices around the globe. To learn more, visit evidation.com, or follow us on Twitter @evidation

CardioGen Sciences

Seed Round in 2014
CardioGen Sciences is a biotechnology company that develops and offers gene therapy solutions for orphan-inherited arrhythmogenic diseases. It was founded in 2014 and is based in Palo Alto, California.

Womply

Venture Round in 2014
Our mission is to help local businesses thrive in a digital world. Founded in 2011, Womply is a local commerce platform that provides apps, APIs, marketing, and financial tools to make local commerce happen for over 500,000 American businesses and their customers. All of Womply’s products and services are powered by the Womply Commerce Graph, a proprietary data asset that offers the most complete view of local commerce.

LiquidM

Venture Round in 2014
LiquidM’s modular cloud-based software allows agencies and trading desks to run their ad tech infrastructure on a standardized, open platform that is customizable to their individual needs. LiquidM uniquely combines media, data, technology, and strategy to allow the audience to reach scale. LiquidM provides more efficiency, greater control, and deeper insights into media planning and buying, to drive better results. Integrated data management, audience targeting, and inventory procurement drive success in the mobile display media marketplace.

CardioDx

Private Equity Round in 2014
CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures.

Signal Vine

Seed Round in 2014
Signal Vine is a text messaging platform that uses Blended Messaging to reach students where they operate most while incorporating the benefits of AI to save staff time. The company's s platform empowers customers to combine text messaging with student data to deliver personalized information, prompt timely action, and ultimately improve outcomes for higher education organizations, nonprofits, and government programs. By nudging students, alumni, and staff with personal messages on key deadlines, appointments, and offers of support, administrators can improve engagement and in turn enrollment and persistence. It was founded in 2013 and is headquartered in Alexandria, Virginia, United States.

Biomimedica

Venture Round in 2014
Biomimedica is a medical device company that is pioneering new approaches to joint repair through its proprietary, synthetic cartilage technology. It was founded in 2007 and is based in South San Francisco, California, United States.

Twist Bioscience

Series B in 2014
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development. At Twist Bioscience Corporation, they work in the service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. They believe that the faster their customers succeed, the better for all of them, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to their customers. their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. Twist Bioscience was founded in 2013 and is headquartered in San Francisco, California.

Reify Health

Seed Round in 2014
Reify Health provides cloud-based software that helps accelerate the development of new, life-saving therapies. The company's system accelerates enrollment timelines and the overall pace of research, enabling research sponsors and coordinators to focus on the actions that impact clinical research success. Reify Health product StudyTeam is a cloud-based software that helps clinical trial teams achieve faster, more predictable enrollment while eliminating the tedious work that saps productivity and study budget. It gives sponsors, CROs, and clinical research sites earlier visibility into the full enrollment picture, and the insight they need to focus on people and capital on work that yields the greatest return.

Aegis Surgical

Venture Round in 2014
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis.

Twist Bioscience

Series A in 2014
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development. At Twist Bioscience Corporation, they work in the service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. They believe that the faster their customers succeed, the better for all of them, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to their customers. their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. Twist Bioscience was founded in 2013 and is headquartered in San Francisco, California.

Maverix Biomics

Series A in 2014
Maverix Biomics brings together decades of experience and expertise in biologic research, bioinformatics, and enterprise application software development from many of today’s leading research institutions and technology companies. Their team combines leadership from successful Silicon Valley companies with world-class researchers from the University of California, Santa Cruz, to focus on one simple mission: to provide research scientists with an open, cloud-based platform integrating best-in-class open-source software that anticipates user needs, enables communities of discovery, and integrates data in context with the latest biomic information for viral, bacterial, vertebrate, and plant genomes.

Womply

Venture Round in 2014
Our mission is to help local businesses thrive in a digital world. Founded in 2011, Womply is a local commerce platform that provides apps, APIs, marketing, and financial tools to make local commerce happen for over 500,000 American businesses and their customers. All of Womply’s products and services are powered by the Womply Commerce Graph, a proprietary data asset that offers the most complete view of local commerce.

Indi Molecular

Seed Round in 2013
Indi Molecular is an emerging life sciences company that is developing a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. PCCs were created in collaboration with the California Institute of Technology using “click chemistry,” a synthetic process that allows scientists to permanently join (“click”) together molecular components with remarkable precision and stability. PCCs offer the promise of improved selectivity, superior binding affinity, fully synthetic composition and a vastly low molecular weight compared to monoclonal antibodies, the current standard for identifying biomarkers in most diagnostics platforms – and in many therapeutic uses. The company launched as a spinout from its parent company Integrated Diagnostics (Indi) in 2013 with a $1.5 million seed round led by InterWest Partners together with several angel investors.

RallyPoint

Series A in 2013
RallyPoint is an online military network with 2 million service members, veterans, and their civilian supporters (family, recruiters, etc.). RallyPoint's mission is to help all members of the military community lead more successful and fulfilling lives. Members can build their professional network, connect with other members in a safe environment, and explore career opportunities both within the military and in the private sector. Bob McDonald, the retired P&G CEO and the 8th Secretary of Veterans Affairs is the chairman of RallyPoint's board. RallyPoint provides employers highly targeted tools for hiring from and advertising into the military community.

LiquidM

Series A in 2013
LiquidM’s modular cloud-based software allows agencies and trading desks to run their ad tech infrastructure on a standardized, open platform that is customizable to their individual needs. LiquidM uniquely combines media, data, technology, and strategy to allow the audience to reach scale. LiquidM provides more efficiency, greater control, and deeper insights into media planning and buying, to drive better results. Integrated data management, audience targeting, and inventory procurement drive success in the mobile display media marketplace.

Lark

Venture Round in 2013
Lark is a developer of chronic disease prevention and management platform used to prevent chronic conditions. The company uses cutting-edge AI combined with human coaches and connected devices to provide real-time, personalized, 24/7 support, and counseling to help users make healthier choices and manage their conditions. Its CDC-recognized Diabetes Prevention Program, Wellness Program, Diabetes Care Program, and Hypertension Program have 1.5 million users and have demonstrated clinically validated improved health outcomes published in 11 peer-reviewed journals and analyst reports. Lark was founded by Julia Hu and Jeff Zira in 2011 and is headquartered in Mountain View, California.

Profusa

Venture Round in 2013
Profusa, Inc. operates in the health care sector. It is dedicated to the development of a new generation of biointegrated sensors that empowers the individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. The company was incorporated in 2009 and is based in Cupertino, California.

Keepsafe

Series A in 2013
Keepsafe makes privacy in the digital world as easy as it is in the physical world. For consumers who want ownership over their digital privacy and a simple way to manage it, Keepsafe’s suite of apps, including Keepsafe Photos, Keepsafe Documents, and AppLock, let you keep personal items private and share them safely. It’s a hub for all of your most important things.

Arterys

Seed Round in 2013
Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions.

Evidation Health

Seed Round in 2013
Evidation measures health in everyday life and enables anyone to participate in groundbreaking research and health programs. Built upon a foundation of user privacy and control over permissioned health data, Evidation's Achievement platform is trusted by millions of individuals—generating data with unprecedented speed, scale, and rigor. We partner with leading healthcare companies to understand health and disease outside the clinic walls. Guided by our mission to enable and empower everyone to participate in better health outcomes, Evidation is working to bring people individualized, proactive, and accessible healthcare—faster. Founded in 2012, Evidation Heath is headquartered in California. We collaborate as a distributed team with additional offices around the globe. To learn more, visit evidation.com, or follow us on Twitter @evidation

Synecor

Venture Round in 2013
Synecor evolved from the confluence of several synergistic strategic relationships, initially in the field of interventional cardiology, but has expanded its field to include all medical specialties such as obesity, spine therapeutics, and more. Synecor was founded by Dr. Richard Stack after two decades of collaboration with leading cardiologists, clinician-inventors, and scientists from across the nation and as an outgrowth of close working relationships among corporate leaders in the medical device industry, and experts at Duke University. Mr. William Starling, a well-known Silicon Valley medical device entrepreneur/executive with a successful 27-year career in the high technology cardiovascular device industry, partnered with Dr. Stack to co-manage Synecor and form strategic relationships with leading venture capital partnerships (Delphi Ventures and Frazier & Company) and a leading investment bank (Deutsche Banc Alex. Brown). To complete the partner team, Dr. Stack and Mr. Starling also partnered with major life sciences corporations with vast resources and knowledge (Guidant and GE Medical Systems).

HealthTap

Series B in 2013
HealthTap is a virtual-first, affordable urgent and primary care clinic, providing top-quality physician care equitably nationwide to all Americans, with or without insurance.

Proteus Digital Health

Series F in 2013
Proteus Digital Health® is creating a new category of pharmaceuticals: Digital Medicines. Digital Medicines includes drugs that communicate when they’ve been taken, wearable sensors that capture physiologic response, applications that support patient self-care and physician decision making and data analytics to serve the needs of doctors and health systems. The goal of Digital Medicines is to empower patients and their families, enable physicians and health systems to more effectively manage risk and ensure that outcomes are reliably achieved.

Esperion

Venture Round in 2013
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Reify Health

Debt Financing in 2013
Reify Health provides cloud-based software that helps accelerate the development of new, life-saving therapies. The company's system accelerates enrollment timelines and the overall pace of research, enabling research sponsors and coordinators to focus on the actions that impact clinical research success. Reify Health product StudyTeam is a cloud-based software that helps clinical trial teams achieve faster, more predictable enrollment while eliminating the tedious work that saps productivity and study budget. It gives sponsors, CROs, and clinical research sites earlier visibility into the full enrollment picture, and the insight they need to focus on people and capital on work that yields the greatest return.

Arterys

Seed Round in 2013
Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions.

CardioDx

Private Equity Round in 2012
CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures.

Biomimedica

Series B in 2012
Biomimedica is a medical device company that is pioneering new approaches to joint repair through its proprietary, synthetic cartilage technology. It was founded in 2007 and is based in South San Francisco, California, United States.

Reify Health

Seed Round in 2012
Reify Health provides cloud-based software that helps accelerate the development of new, life-saving therapies. The company's system accelerates enrollment timelines and the overall pace of research, enabling research sponsors and coordinators to focus on the actions that impact clinical research success. Reify Health product StudyTeam is a cloud-based software that helps clinical trial teams achieve faster, more predictable enrollment while eliminating the tedious work that saps productivity and study budget. It gives sponsors, CROs, and clinical research sites earlier visibility into the full enrollment picture, and the insight they need to focus on people and capital on work that yields the greatest return.

Terra Bella

Series C in 2012
Terra Bella is a private company that provides commercial, high-resolution satellite imagery and high-definition video and analytics services. It analyzes the movement of goods and people; and provides visual data about supply chains, shipping, industrial plant activity, and humanitarian relief efforts. Terra Bella (originally Skybox Imaging) was co-founded by Dan Berkenstock, Julian Mann, John Fenwick, and Ching-Yu Hu in 2009 and is based in Mountain View, California, United States.

Keepsafe

Seed Round in 2012
Keepsafe makes privacy in the digital world as easy as it is in the physical world. For consumers who want ownership over their digital privacy and a simple way to manage it, Keepsafe’s suite of apps, including Keepsafe Photos, Keepsafe Documents, and AppLock, let you keep personal items private and share them safely. It’s a hub for all of your most important things.

HealthTap

Series A in 2011
HealthTap is a virtual-first, affordable urgent and primary care clinic, providing top-quality physician care equitably nationwide to all Americans, with or without insurance.

ICON Aircraft

Series C in 2011
ICON Aircraft’s mission is to accelerate the democratization of personal flight and 3-D mobility. ICON creates consumer-friendly, safe, technologically advanced aircraft that make the adventure of flying more accessible to mainstream consumers. ICON’s first aircraft is the A5, an amphibious sport plane that fuses outstanding aeronautical engineering with world-class product design and unprecedented safety features. The A5 is the world’s first production aircraft that is spin-resistant, making it arguably one of the safest small aircraft ever created. The A5 has won some of the world’s most prestigious design awards and has inspired a global following. The company culture is defined by an entrepreneurial, fast-paced, performance-driven meritocracy where intelligent risk-taking is encouraged and the organizational structure is flat and collaborative. ICON seeks A-players who are a strong cultural fit and driven to change the world by creating truly innovative products.

HealthTap

Seed Round in 2011
HealthTap is a virtual-first, affordable urgent and primary care clinic, providing top-quality physician care equitably nationwide to all Americans, with or without insurance.

Immunocellular Therapeutics

Venture Round in 2011
ImmunoCellular Therapeuti is a clinical-stage biotechnology company. It is engaged in developing immune-based therapies for the treatment of cancers which can elicit an immune response against several antigens. The company has developed ICT-107, which is a dendritic cell (DC) immunotherapy for the treatment of newly diagnosed glioblastoma multiforme (GBM), which is a lethal type of brain cancer. It develops Immunotherapies for treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.

Chimerix

Series F in 2011
Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans. Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies. CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases. Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing. Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.

Ooma

Debt Financing in 2011
Ooma (NYSE: OOMA) creates powerful connected experiences for businesses and consumers, delivered from its smart cloud-based SaaS platform. For businesses of all sizes, Ooma provides advanced voice and collaboration features that are flexible and scalable. For consumers, Ooma provides PureVoice HD voice quality, advanced functionality and integration with their mobile devices. Ooma’s groundbreaking home security solution delivers a full range of wireless security sensors and a smart video camera, putting consumers in charge of protecting their homes. Learn more at www.ooma.com.
Rapidscan Pharma Solutions (RPS, Inc.) was formed in 2010 by leading members of the team that discovered and developed regadenoson, a new pharmacological stress agent used in the diagnosis and risk stratification of cardiovascular disease. RPS, Inc. has licensed the rights to sell regadenoson in Europe and other select territories. Today, there are over 15M people in Europe with coronary artery disease, of which 1.5M patients undergo a myocardial perfusion imaging (MPI) procedure in the diagnosis of coronary artery disease (CAD).

Provade

Series F in 2010
Provade is the leader in enterprise managed services for the Global 2000. Built around Oracle's enterprise platform, Provade’s services and solutions help medium- and large-sized businesses realize the significant benefits that contingent workforce management and spend management often promise but rarely deliver: measurable savings, minimal investment, simple integration, and greater visibility. Their approach offers: Managed services for contingent workforce management and procurement that enable your organization to increase efficiency, gain visibility and reduce cost. Subscription-based, on-demand applications that are quick to deploy and designed to leverage your existing financial and HR infrastructure. Professional services that enhance both your procurement strategy and technical implementation.

CardioDx

Series D in 2010
CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures.

OfferIQ

Venture Round in 2010
OfferIQ bridges the gap between mobile coupon delivery and redemption in the physical shopping world.

HighTower Advisors

Venture Round in 2010
Hightower is a wealth management organization that offers investing, financial, and retirement planning services to individuals, charities, and family offices, as well as 401(k) consultation and cash management for corporations.

Kii

Series A in 2010
Kii Corporation, established in July 2010 through the merger of Servo Software and Synclore Corporation, specializes in providing Internet of Things (IoT) platforms and solutions for various sectors, including Smart Cities, Smart Buildings, Smart Logistics, and healthcare. The company offers a mobile backend-as-a-service platform that simplifies the development of IoT and mobile applications by managing multiple vendors and providing essential backend functionalities, such as user management and push notifications. This approach allows businesses to reduce both development and operational costs by eliminating the need to manage or operate servers, thereby streamlining the application development process.

Coapt Systems

Debt Financing in 2009
Coapt Systems, Inc. engages in the design, development, manufacture, and marketing of bio-absorbable implants for use in soft tissue fixation during facial cosmetic surgery procedures. It offers ENDOTINE Forehead 3.0, a bioabsorbable brow fixation device; ENDOTINE Forehead Instrument Kits that comprise insertion tools, drill bits, and sterilization trays with lids; ENDOTINE Triple 3.0, the bioabsorbable brow fixation devices with disposable drill bits and insertion tools; ENDOTINE TransBleph 3.0, a bioabsorbable upper lid and brow fixation devices. The company also provides ENDOTINE Midface ST 4.5, a bioabsorbable midface suspension devices; ENDOTINE Ribbon, a bioabsorbable fixation devices; Coapt Manual Surgical Drills, the manual surgical hand drills for use with ENDOTINE implants; and SurgiWire Incisionless Dissectors, the subcutaneous The Endotine product line was bought by MicroAire, a surgical device manufacturer in Charlottesville, VA, in August 2010.

Stratavia

Debt Financing in 2009
Stratavia is a leading provider of data center automation software solutions. Specifically, Stratavia develops and markets database, server and run book automation software which helps customers reduce the cost of operating their enterprise environments. Founded in 2001, Stratavia is privately held and venture funded and is headquartered in Denver, Colorado.

Servo Software

Series B in 2009
Kii (Formerly Servo Software) delivers a set of applications, APIs and SDKs to device manufacturers, mobile network operators, and end users, which help users to sync, search, and share mobile content on their and their friends' phones. The Kii company is the result of the merger of Synclore Corp. and Servo Software, Inc. in July 2010. Based in Tokyo, Japan and Silicon Valley, Calif., Kii has global offices in China, Germany and Spain. Kii Capital, L.P. is a venture fund which invests into mobile applications.

Brilliant Telecommunications

Venture Round in 2009
Brilliant Telecommunications, Inc. designs, develops, and distributes network timing, management, and synchronization solutions. Its products include Zurich Z-1000, a zero footprint, outdoor, and pole-mounted Network Time Protocol server that embodies its own timing management interface to provide tools for diagnosis, monitoring, and alarms; Cern C-2000, which is a Primary Reference Source and Clock that provides time stamping accuracy and configurability; and BT-750, a network timing client that delivers multiple synchronous outputs in a flexible platform. The company serves financial markets, legal institutions, telecommunication companies, and manufacturing organizations. Brilliant Telecommunications, Inc. was founded in 2004 and is based in Campbell, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.